Sailong Pharmaceutical Group Co., Ltd. (002898.SZ)
CNY 7.3
(-2.41%)
CNY 7.3
(-2.41%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 813.84 Million CNY | -4.03% |
| 2022 | 847.99 Million CNY | -3.94% |
| 2021 | 882.78 Million CNY | 8.46% |
| 2020 | 813.95 Million CNY | -2.63% |
| 2019 | 835.97 Million CNY | 10.6% |
| 2018 | 755.84 Million CNY | 5.69% |
| 2017 | 715.13 Million CNY | 133.97% |
| 2016 | 305.65 Million CNY | 15.46% |
| 2015 | 264.73 Million CNY | 39.71% |
| 2014 | 189.48 Million CNY | 1.65% |
| 2013 | 186.4 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 784.3 Million CNY | -3.63% |
| 2024 Q3 | 841.07 Million CNY | 5.6% |
| 2024 Q2 | 796.47 Million CNY | 1.55% |
| 2023 Q1 | 827.25 Million CNY | -2.44% |
| 2023 Q3 | 812.63 Million CNY | -5.2% |
| 2023 Q2 | 857.21 Million CNY | 3.62% |
| 2023 Q4 | 813.84 Million CNY | 0.15% |
| 2023 FY | 813.84 Million CNY | -4.03% |
| 2022 Q3 | 865.69 Million CNY | -0.75% |
| 2022 Q1 | 871.76 Million CNY | -1.25% |
| 2022 FY | 847.99 Million CNY | -3.94% |
| 2022 Q4 | 847.99 Million CNY | -2.05% |
| 2022 Q2 | 872.25 Million CNY | 0.06% |
| 2021 Q3 | 860.46 Million CNY | -0.43% |
| 2021 FY | 882.78 Million CNY | 8.46% |
| 2021 Q4 | 882.78 Million CNY | 2.59% |
| 2021 Q2 | 864.15 Million CNY | -0.28% |
| 2021 Q1 | 866.56 Million CNY | 6.46% |
| 2020 Q4 | 813.95 Million CNY | -8.76% |
| 2020 FY | 813.95 Million CNY | -2.63% |
| 2020 Q2 | 905.08 Million CNY | 7.22% |
| 2020 Q1 | 844.11 Million CNY | 0.97% |
| 2020 Q3 | 892.06 Million CNY | -1.44% |
| 2019 Q3 | 801.64 Million CNY | -1.64% |
| 2019 Q2 | 815.01 Million CNY | 13.13% |
| 2019 Q1 | 720.41 Million CNY | -4.69% |
| 2019 FY | 835.97 Million CNY | 10.6% |
| 2019 Q4 | 835.97 Million CNY | 4.28% |
| 2018 FY | 755.84 Million CNY | 5.69% |
| 2018 Q4 | 755.84 Million CNY | 2.62% |
| 2018 Q2 | 735.09 Million CNY | 1.49% |
| 2018 Q3 | 736.52 Million CNY | 0.2% |
| 2018 Q1 | 724.32 Million CNY | 1.28% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 FY | 715.13 Million CNY | 133.97% |
| 2017 Q4 | 715.13 Million CNY | 4.49% |
| 2017 Q3 | 684.4 Million CNY | 89.76% |
| 2017 Q2 | 360.66 Million CNY | 0.0% |
| 2016 FY | 305.65 Million CNY | 15.46% |
| 2016 Q4 | 305.65 Million CNY | 0.0% |
| 2015 FY | 264.73 Million CNY | 39.71% |
| 2014 FY | 189.48 Million CNY | 1.65% |
| 2013 FY | 186.4 Million CNY | 0.0% |